Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) (REVEAL-SCAN)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02959489 |
|
Recruitment Status : Unknown
Verified April 2021 by Robert C. Green, MD, MPH, Brigham and Women's Hospital.
Recruitment status was: Active, not recruiting
First Posted : November 9, 2016
Last Update Posted : May 5, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer Disease Amyloid Beta-Peptides Risk Assessment Education Neuropsychological Tests Neuroimaging | Behavioral: Alzheimer's Disease Risk Disclosure Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure | Not Applicable |
Alzheimer's disease (AD) is a brain disease and is the most common form of dementia. Clinical trials for the prevention of AD have been moving to enroll subjects at increasingly earlier time-points, and are now focusing upon individuals who are not only cognitively normal but also have biomarkers associated with an increased risk of developing AD. Detecting one specific biomarker on brain scans, i.e. amyloid-beta protein, is currently used to inform diagnoses in cognitively impaired individuals, and its use may expand to pre-clinical AD cases as preventive therapies are developed.
In the REVEAL-SCAN clinical trial, the investigators are examining the psychological and behavioral impact of learning "elevated" and "not elevated" amyloid neuroimaging results pertaining to the risk of progressing to Alzheimer's disease dementia by age 85 among cognitively normal older adults. The study's goal is to learn how to communicate these amyloid brain scan results and the risk of developing AD dementia by age 85 in a diverse population of cognitively normal older adults. Findings will be relevant to future decision-making in research trials and clinical practices.
Study sites will enroll older, cognitively normal individuals (approx. 370 total) using APOE genotyping to enrich the enrollment sample such that roughly 100 of those scanned will have elevated amyloid brain scan results. From this enriched sample, participants (approximately 25% African-American) will all receive their Alzheimer's Disease Dementia Risk Assessment based on known risk factors. Half of the participants will be randomized to also learn their amyloid brain scan result at that time, while the other half will learn their scan result 6 months later. Cognitive, psychological, and behavioral outcomes will be compared between these two groups. Participants will be followed for up to 9 months with up to 7 in-person visits and 5 phone calls.
REVEAL-SCAN is the first multisite randomized clinical trial to explore the benefits, risks and limitations of disclosing amyloid results, and will help researchers and clinicians understand downstream implications of this emerging technology as it becomes increasingly utilized to compile comprehensive neuroimaging profiles for older adults at risk for developing Alzheimer's disease dementia.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 315 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Health Services Research |
| Official Title: | Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) |
| Study Start Date : | November 2016 |
| Actual Primary Completion Date : | May 13, 2020 |
| Estimated Study Completion Date : | December 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Amyloid Brain Imaging Non-Disclosure
Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.
|
Behavioral: Alzheimer's Disease Risk Disclosure
Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type. |
|
Experimental: Amyloid Brain Imaging Disclosure
Subjects will receive both their "elevated" or "not elevated" amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry.
|
Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
Subjects will learn their own "elevated" or "not elevated" amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type. |
- Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure [ Time Frame: Baseline, 6 weeks post-disclosure, 6-months post-disclosure ]Assessed via the A4 Study's Preclinical Alzheimer Cognitive Composite (ADCS-PACC) battery, which combines tests that measure episodic memory, timed executive function, and global cognition.
- Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure. [ Time Frame: Baseline, 6 weeks post-disclosure, 6-months post-disclosure ]Psychological distress will be measured between and within participants at the same and different study time points, and will be based on participants' scores on scales and questionnaires in terms of the following related variables of psychological distress: anxiety and depression, test-specific distress, psychological impact of disclosure, quality of life, perceived time and subjective cognition.
- Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information. [ Time Frame: Baseline, 6 weeks post-disclosure, 6-months post-disclosure ]Assessed in participant surveys via questions evaluating: health behavior changes, advanced planning, insurance changes (i.e. purchasing or altering long-term care policies), medication changes, willingness to enroll in clinical research and tolerance of research risk.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 65 Years to 80 Years (Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- English-speaking individuals (65-80 years old) with normal cognition
- Individuals with at least one first-degree relative with Alzheimer's disease (parent, sibling, child)
- Individuals who have a close friend, relative or spouse (18+) willing to be a study partner. Study partners complete surveys and interviews, accompany the study subject to the second in-person study visit, and may be asked to attend other/all study visits.
- Individuals who are willing to give a cheek swab sample to undergo blinded (undisclosed) APOE genotyping
- Individuals willing to participate in a randomized clinical trial of amyloid imaging disclosure
Exclusion Criteria:
- Individuals who have suffered from a stroke or head trauma
- Individuals who have active medical or psychiatric illness that is unstable or progressive
- Individuals who are taking acetylcholinesterase inhibitors of memantine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02959489
| United States, Massachusetts | |
| Brigham and Women's Hospital | |
| Boston, Massachusetts, United States, 02115 | |
| United States, Michigan | |
| University of Michigan | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, North Carolina | |
| Duke University | |
| Durham, North Carolina, United States, 27705 | |
| United States, Pennsylvania | |
| University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Principal Investigator: | Robert C Green, MD, MPH | Brigham and Women's Hospital | |
| Principal Investigator: | Jason Karlawish, MD | University of Pennsylvania | |
| Principal Investigator: | J. Scott Roberts, PhD | University of Michigan | |
| Principal Investigator: | Kathleen Welsh-Boomer, PhD | Duke University |
Documents provided by Robert C. Green, MD, MPH, Brigham and Women's Hospital:
| Responsible Party: | Robert C. Green, MD, MPH, Principal Investigator of REVEAL-SCAN, Brigham and Women's Hospital |
| ClinicalTrials.gov Identifier: | NCT02959489 |
| Other Study ID Numbers: |
RF1AG047866 ( U.S. NIH Grant/Contract ) 1RF1AG047866-01A1 ( U.S. NIH Grant/Contract ) |
| First Posted: | November 9, 2016 Key Record Dates |
| Last Update Posted: | May 5, 2021 |
| Last Verified: | April 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
Alzheimer Disease Amyloidosis Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Proteostasis Deficiencies Metabolic Diseases |